Harbour Annouces Global Partnership with Kelun-Biotech to Develop and Commercialize A167 (Anti-PD-L1 mAb)
Shots:
- Under the licensing deal Harbour has global rights of A167 (excl. Greater China)- to treat multiple solid and hematological cancers
- Kelun-Biotech will receive an upfront of >$350mn in addition to royalties
- A167 is under clinical Ph I & II in China targeting lymphoma and solid tumors
Ref: Harbour Biomed | Image: Business wire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com